Literature DB >> 9426427

Survival after surgical treatment for primary hyperparathyroidism.

J A Söreide1, J A van Heerden, C S Grant, C Yau Lo, C Schleck, D M Ilstrup.   

Abstract

BACKGROUND: Reports have suggested that patients with primary hyperparathyroidism (pHPT) are at increased risk for premature death, even when they reach normocalcemia. This study addresses factors that may be of relevance for long-term outcome.
METHODS: Between 1980 and 1984, 1052 patients (27% men and 73% women; median age, 59 years) underwent initial cervical exploration for pHPT. Long-term follow-up was obtained with regard to overall survival and cause of death. By using univariate and multivariate (Cox) survival analysis, subgroups of patients were compared.
RESULTS: Median follow-up was 12 years (range, 0 to 15 years). Overall, survival was not decreased compared with the expected survival of a gender- and age-matched midwest population. Survival was better in patients with a history of kidney stones (p = 0.044), without osteoporosis (p = 0.004), and without muscle weakness (p = 0.013).
CONCLUSIONS: Decreased long-term survival was not evident in this study. Age at the time of initial surgical treatment and the degree of endocrine activity of the diseased glands appear to be the most important independent prognostic factors for survival. Comparison of these data to prior Scandinavian data is not justified, principally because of the less advanced stage of disease in this study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426427     DOI: 10.1016/s0039-6060(97)90216-6

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

Review 1.  Parathyroidectomy for asymptomatic primary hyperparathyroidism (PHPT): is it worth the risk?

Authors:  J Rastad
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

2.  Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism.

Authors:  E Lundgren; E Szabo; S Ljunghall; R Bergström; L Holmberg; J Rastad
Journal:  BMJ       Date:  1998-09-26

3.  New perspectives in the management of primary hyperparathyroidism.

Authors:  John Ayuk; Mark S Cooper; Neil J L Gittoes
Journal:  Ther Adv Endocrinol Metab       Date:  2010-10       Impact factor: 3.565

4.  Association of Patient Frailty With Increased Morbidity After Common Ambulatory General Surgery Operations.

Authors:  Carolyn D Seib; Holly Rochefort; Kathryn Chomsky-Higgins; Jessica E Gosnell; Insoo Suh; Wen T Shen; Quan-Yang Duh; Emily Finlayson
Journal:  JAMA Surg       Date:  2018-02-01       Impact factor: 14.766

5.  How long should we follow patients after apparently curative parathyroidectomy?

Authors:  Irene Lou; Courtney Balentine; Samuel Clarkson; David F Schneider; Rebecca S Sippel; Herbert Chen
Journal:  Surgery       Date:  2016-11-15       Impact factor: 3.982

6.  Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy.

Authors:  P Farahnak; M Ring; K Caidahl; L-O Farnebo; M J Eriksson; I-L Nilsson
Journal:  Eur J Endocrinol       Date:  2010-06-18       Impact factor: 6.664

7.  Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients.

Authors:  Alper Kepez; Ayla Harmanci; Tuncay Hazirolan; Mehlika Isildak; Ugur Kocabas; Ahmet Ates; Orcun Ciftci; Lale Tokgozoglu; Alper Gürlek
Journal:  Int J Cardiovasc Imaging       Date:  2008-09-11       Impact factor: 2.357

Review 8.  Cardiovascular aspects of primary hyperparathyroidism.

Authors:  M D Walker; S J Silverberg
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

Review 9.  Nontraditional manifestations of primary hyperparathyroidism.

Authors:  Marcella Donovan Walker; Mishaela Rubin; Shonni J Silverberg
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

Review 10.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.